Despite an unprecedented clinical success, not all CRC patients respond to anti-PD-1-PDL1 therapeutics underscoring a need for other therapeutic targets that perturb several aspects of tumorigenesis. This evidence concerns the gene PDCD1 and colorectal carcinoma.